޲Ʊ

޲Ʊ’s CEO Naito Participated in Online Event “Deliver 18 new treatments by 2028 – The future of partnerships and role of Japan”

July 20, 2021

޲Ʊ., Ltd. (޲Ʊ) is jointly developing new drugs for neglected tropical diseases with the Drugs for Neglected Diseases initiative (DNDi), an international non-profit organization. ޲Ʊ’s CEO Haruo Naito participated in DNDi’s online event “Deliver 18 new treatments by 2028 – The future of partnerships and role of Japan” which was held on June 30, 2021. Currently, ޲Ʊ and DNDi are jointly developing ޲Ʊ’s in-house discovered antifungal agent fosravuconazole (E1224) as a treatment for mycetoma, a neglected tropical disease. Furthermore, ޲Ʊ and DNDi have established a long-term partnership and are collaborating on other neglected tropical diseases such as leishmaniasis.

Participants of the event

DNDi has announced a new strategic plan aiming to deliver 18 new treatments by 2028 in collaboration with partners. A panel of leaders and experts of industry, government and academia including ޲Ʊ’s Naito discussed what Japan can do for neglected patients and what is needed for future R&D partnerships. Please visit to watch the event. 

Event held on June 30, 2021

޲Ʊ will continue to work on developing new drugs for neglected tropical diseases such as mycetoma and leishmaniasis with its global partners, including DNDi.

〶〶

〶〶

Share

Related Links